RaySearch Laboratories ABLTS:0GRZ +3.20%83 Piotroski F-Score is 9 as of Jul. 03, 2026, which is 50% above its 10-year median of 6.00. GuruFocus rates LTS:0GRZ with a GF Score™ of 83/100 and a GF Value™ of kr188.99 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 651 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 99.85% on this metric.
Good Sign:
Piotroski F-Score is 9, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
RaySearch Laboratories AB has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for RaySearch Laboratories AB's Piotroski F-Score or its related term are showing as below:
LTS:0GRZ'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 6 Max: 9
Current: 9
During the past 13 years, the highest Piotroski F-Score of RaySearch Laboratories AB was 9. The lowest was 3. And the median was 6.
RaySearch Laboratories AB (LTS:0GRZ) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
RaySearch Laboratories AB Piotroski F-Score Related Terms
RaySearch Laboratories AB Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0GRZ vs VEEV, BTSG, TEM: Piotroski F-Score Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB Piotroski F-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
RaySearch Laboratories AB's current Net Income (TTM) was 224.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
RaySearch Laboratories AB's current Cash Flow from Operations (TTM) was 349.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
RaySearch Laboratories AB's return on assets of this year was 0.10888501. RaySearch Laboratories AB's return on assets of last year was 0.10833775.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
RaySearch Laboratories AB's gearing of this year was 0.14922536. RaySearch Laboratories AB's gearing of last year was 0.18122869.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
RaySearch Laboratories AB's current ratio of this year was 1.79225852. RaySearch Laboratories AB's current ratio of last year was 1.53257191.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
RaySearch Laboratories AB's number of shares in issue this year was 34.283. RaySearch Laboratories AB's number of shares in issue last year was 34.283.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
RaySearch Laboratories AB's gross margin of this year was 0.92370896. RaySearch Laboratories AB's gross margin of last year was 0.9190863.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
RaySearch Laboratories AB's asset turnover of this year was 0.63285737. RaySearch Laboratories AB's asset turnover of last year was 0.61334356.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
=
9
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
RaySearch Laboratories AB has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
RaySearch Laboratories AB (LTS:0GRZ) has a Piotroski F-Score of 9 as of Jul. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on RaySearch Laboratories AB and its competitors. This is 50% above median its historical median of 6.00. Over the past decade, RaySearch Laboratories AB's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, RaySearch Laboratories AB ranks #1 out of 651 companies in the Healthcare Providers & Services industry, placing it in the top 0.2%.
Is RaySearch Laboratories AB's Piotroski F-Score too high?
RaySearch Laboratories AB's current Piotroski F-Score of 9 is 50% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. RaySearch Laboratories AB's value of 9 is 80% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #1 out of 651 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Piotroski F-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #1 out of 651 companies for Piotroski F-Score. This places RaySearch Laboratories AB in the top 0% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. RaySearch Laboratories AB's value of 9 is 80% above this benchmark. Historically, RaySearch Laboratories AB's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 651 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current Piotroski F-Score of 9 is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current Piotroski F-Score is 9, which is 50% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (LTS:0GRZ) is currently considered Modestly Overvalued. The stock's GF Value™ is kr188.99, compared to a current price of kr232.20 — trading 22.9% above its estimated fair value. The current Piotroski F-Score is 9, which is 50% above median its 10-year median of 6.00 and 80% above the Healthcare Providers & Services industry median of 5.00. RaySearch Laboratories AB's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For RaySearch Laboratories AB (LTS:0GRZ), the current Piotroski F-Score is 9 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (LTS:0GRZ) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of kr232.20 is trading 22.9% above its estimated GF Value™ of kr188.99.
GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.
Key valuation signals for LTS:0GRZ:
Piotroski F-Score: 9 (50% above median its 10-year median of 6.00)
GF Value™: kr188.99 vs. price of kr232.20 (22.9% above fair value)
Industry Position: 80% above the Healthcare Providers & Services median (#1 of 651)
No single metric tells the full story. See the LTS:0GRZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
83GF Score
Get the complete analysis for LTS:0GRZ
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0GRZ has been successfully added to your 
